Search Results - "de Bono, Johann S."

Tumor clone dynamics in lethal prostate cancer by Carreira, Suzanne, Romanel, Alessandro, Goodall, Jane, Grist, Emily, Ferraldeschi, Roberta, Miranda, Susana, Prandi, Davide, Lorente, David, Frenel, Jean-Sebastien, Pezaro, Carmel, Omlin, Aurelius, Rodrigues, Daniel Nava, Flohr, Penelope, Tunariu, Nina, S de Bono, Johann, Demichelis, Francesca, Attard, Gerhardt

“…It is unclear whether a single clone metastasizes and remains dominant over the course of lethal prostate cancer. We describe the clonal architectural…”
Get more information

Sequencing of agents in castration-resistant prostate cancer by Lorente, David, MD, Mateo, Joaquin, MD, Perez-Lopez, Raquel, MD, de Bono, Johann S, Prof, Attard, Gerhardt, Dr

“…Summary Until 2010, docetaxel was the only agent with proven survival benefit for castration-resistant prostate cancer. The development of cabazitaxel,…”
Get full text

Chromatin to Clinic: The Molecular Rationale for PARP1 Inhibitor Function by Feng, Felix Y., de Bono, Johann S., Rubin, Mark A., Knudsen, Karen E.

“…Poly(ADP-ribose) polymerase 1 (PARP1) inhibitors were recently shown to have potential clinical impact in a number of disease settings, particularly as related…”
Get full text

Abiraterone and Increased Survival in Metastatic Prostate Cancer by de Bono, Johann S, Logothetis, Christopher J, Molina, Arturo, Fizazi, Karim, North, Scott, Chu, Luis, Chi, Kim N, Jones, Robert J, Goodman, Oscar B, Saad, Fred, Staffurth, John N, Mainwaring, Paul, Harland, Stephen, Flaig, Thomas W, Hutson, Thomas E, Cheng, Tina, Patterson, Helen, Hainsworth, John D, Ryan, Charles J, Sternberg, Cora N, Ellard, Susan L, Fléchon, Aude, Saleh, Mansoor, Scholz, Mark, Efstathiou, Eleni, Zivi, Andrea, Bianchini, Diletta, Loriot, Yohann, Chieffo, Nicole, Kheoh, Thian, Haqq, Christopher M, Scher, Howard I

“…In this study, abiraterone acetate inhibited androgen synthesis and prolonged survival by 4 months among men with castration-resistant prostate cancer that had…”
Get full text

Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer by Ligthart, Sjoerd T, Coumans, Frank A W, Bidard, Francois-Clement, Simkens, Lieke H J, Punt, Cornelis J A, de Groot, Marco R, Attard, Gerhardt, de Bono, Johann S, Pierga, Jean-Yves, Terstappen, Leon W M M

“…Presence of circulating tumor cells (CTC) in patients with metastatic breast, colorectal and prostate cancer is indicative for poor prognosis. An automated CTC…”
Get full text

Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology by Nuhn, Philipp, De Bono, Johann S., Fizazi, Karim, Freedland, Stephen J., Grilli, Maurizio, Kantoff, Philip W., Sonpavde, Guru, Sternberg, Cora N., Yegnasubramanian, Srinivasan, Antonarakis, Emmanuel S.

“…Introduction of novel agents for the management of advanced prostate cancer provides a range of treatment options with notable benefits for men with metastatic…”
Get full text

Development of Therapeutic Combinations Targeting Major Cancer Signaling Pathways by YAP, Timothy A, OMLIN, Aurelius, DE BONO, Johann S

“…Signaling networks play key homeostatic processes in living organisms but are commonly hijacked in oncogenesis. Prominent examples include genetically altered…”
Get full text

Prostate carcinogenesis: inflammatory storms by de Bono, Johann S., Guo, Christina, Gurel, Bora, De Marzo, Angelo M., Sfanos, Karen S., Mani, Ram S., Gil, Jesús, Drake, Charles G., Alimonti, Andrea

“…Prostate cancer is a major cause of cancer morbidity and mortality. Intra-prostatic inflammation is a risk factor for prostate carcinogenesis, with diet,…”
Get full text

Alternative splicing in prostate cancer by Paschalis, Alec, Sharp, Adam, Welti, Jonathan C., Neeb, Antje, Raj, Ganesh V., Luo, Jun, Plymate, Stephen R., de Bono, Johann. S.

“…Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development and progression of metastatic prostate cancer. AR-Vs are truncated…”
Get full text

Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer by Paschalis, Alec, Sheehan, Beshara, Riisnaes, Ruth, Rodrigues, Daniel Nava, Gurel, Bora, Bertan, Claudia, Ferreira, Ana, Lambros, Maryou B.K., Seed, George, Yuan, Wei, Dolling, David, Welti, Jon C., Neeb, Antje, Sumanasuriya, Semini, Rescigno, Pasquale, Bianchini, Diletta, Tunariu, Nina, Carreira, Suzanne, Sharp, Adam, Oyen, Wim, de Bono, Johann S.

“…Prostate-specific membrane antigen (PSMA; folate hydrolase) prostate cancer (PC) expression has theranostic utility. To elucidate PC PSMA expression and…”
Get full text

Neutropenia, neutrophilia, and neutrophil–lymphocyte ratio as prognostic markers in patients with metastatic castration-resistant prostate cancer by Meisel, Alexander, de Wit, Ronald, Oudard, Stephane, Sartor, Oliver, Stenner-Liewen, Frank, Shun, Zhenming, Foster, Meredith, Ozatilgan, Ayse, Eisenberger, Mario, de Bono, Johann S.

“…Background and purpose: Chemotherapy-induced neutropenia and neutrophil-to-lymphocyte ratio (NLR) are potentially useful prognostic markers in patients with…”
Get full text

Inactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer by Wu, Yi-Mi, Cieślik, Marcin, Lonigro, Robert J., Vats, Pankaj, Reimers, Melissa A., Cao, Xuhong, Ning, Yu, Wang, Lisha, Kunju, Lakshmi P., de Sarkar, Navonil, Heath, Elisabeth I., Chou, Jonathan, Feng, Felix Y., Nelson, Peter S., de Bono, Johann S., Zou, Weiping, Montgomery, Bruce, Alva, Ajjai, Robinson, Dan R., Chinnaiyan, Arul M.

“…Using integrative genomic analysis of 360 metastatic castration-resistant prostate cancer (mCRPC) samples, we identified a novel subtype of prostate cancer…”
Get full text

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy by Scher, Howard I, Fizazi, Karim, Saad, Fred, Taplin, Mary-Ellen, Sternberg, Cora N, Miller, Kurt, de Wit, Ronald, Mulders, Peter, Chi, Kim N, Shore, Neal D, Armstrong, Andrew J, Flaig, Thomas W, Fléchon, Aude, Mainwaring, Paul, Fleming, Mark, Hainsworth, John D, Hirmand, Mohammad, Selby, Bryan, Seely, Lynn, de Bono, Johann S

“…In a study involving nearly 1200 men with metastatic prostate cancer who had progressive disease after chemotherapy, enzalutamide, a novel androgen-receptor…”
Get full text

DNA Repair in Prostate Cancer: Biology and Clinical Implications by Mateo, Joaquin, Boysen, Gunther, Barbieri, Christopher E, Bryant, Helen E, Castro, Elena, Nelson, Pete S, Olmos, David, Pritchard, Colin C, Rubin, Mark A, de Bono, Johann S

“…Abstract Context For more precise, personalized care in prostate cancer (PC), a new classification based on molecular features relevant for prognostication and…”
Get full text

Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer by Scher, Howard I, Heller, Glenn, Molina, Arturo, Attard, Gerhardt, Danila, Daniel C, Jia, Xiaoyu, Peng, Weimin, Sandhu, Shahneen K, Olmos, David, Riisnaes, Ruth, McCormack, Robert, Burzykowski, Tomasz, Kheoh, Thian, Fleisher, Martin, Buyse, Marc, de Bono, Johann S

“…Trials in castration-resistant prostate cancer (CRPC) need new clinical end points that are valid surrogates for survival. We evaluated circulating tumor cell…”
Get full text

First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours by Ameratunga, Malaka, Braña, Irene, Bono, Petri, Postel-Vinay, Sophie, Plummer, Ruth, Aspegren, John, Korjamo, Timo, Snapir, Amir, de Bono, Johann S

“…Background Bromodomain and extra-terminal domain (BET) proteins are reported to be epigenetic anti-cancer drug targets. This first-in-human study evaluated the…”
Get full text

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study by Ryan, Charles J, Prof, Smith, Matthew R, Prof, Fizazi, Karim, Prof, Saad, Fred, Prof, Mulders, Peter F A, Prof, Sternberg, Cora N, MD, Miller, Kurt, Prof, Logothetis, Christopher J, Prof, Shore, Neal D, MD, Small, Eric J, Prof, Carles, Joan, MD, Flaig, Thomas W, MD, Taplin, Mary-Ellen, MD, Higano, Celestia S, Prof, de Souza, Paul, Prof, de Bono, Johann S, Prof, Griffin, Thomas W, MD, De Porre, Peter, MD, Yu, Margaret K, MD, Park, Youn C, PhD, Li, Jinhui, PhD, Kheoh, Thian, PhD, Naini, Vahid, PharmD, Molina, Arturo, MD, Rathkopf, Dana E, MD

“…Summary Background Abiraterone acetate plus prednisone significantly improved radiographic progression-free survival compared with placebo plus prednisone in…”
Get full text

Androgen Receptor Modulation Optimized for Response—Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7–expressing Metastatic Castration-resistant Prostate Cancer by Taplin, Mary-Ellen, Antonarakis, Emmanuel S., Ferrante, Karen J., Horgan, Kerry, Blumenstein, Brent, Saad, Fred, Luo, Jun, de Bono, Johann S.

“…: Detection of androgen receptor (AR) splice variant-7 (AR-V7) messenger RNA (mRNA) in circulating tumor cells (CTCs) is associated with a suboptimal response…”
Get full text

Activation of MAPK Signaling by CXCR7 Leads to Enzalutamide Resistance in Prostate Cancer by Li, Shangze, Fong, Ka-Wing, Gritsina, Galina, Zhang, Ali, Zhao, Jonathan C, Kim, Jung, Sharp, Adam, Yuan, Wei, Aversa, Caterina, Yang, Ximing J, Nelson, Peter S, Feng, Felix Y, Chinnaiyan, Arul M, de Bono, Johann S, Morrissey, Colm, Rettig, Matthew B, Yu, Jindan

“…Castration-resistant prostate cancer (CRPC) that has developed resistance to the new-generation androgen receptor (AR) antagonist enzalutamide is a lethal…”
Get full text

Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer by Welti, Jonathan, Rodrigues, Daniel Nava, Sharp, Adam, Sun, Shihua, Lorente, David, Riisnaes, Ruth, Figueiredo, Ines, Zafeiriou, Zafeiris, Rescigno, Pasquale, de Bono, Johann S, Plymate, Stephen R

“…Abstract Background The androgen receptor splice variant-7 (AR-V7) has been implicated in the development of castration-resistant prostate cancer (CRPC) and…”
Get full text